Detailed Narrative
Q3 FY25 Financial Performance and Key Drivers
Natco Pharma reported a consolidated total revenue of ₹651.1 crores for Q3 FY25, a notable decrease from ₹795.6 crores in the same period last year. Net profit also saw a significant decline, falling to ₹132.4 crores from ₹212.7 crores YoY. This 'soft quarter' was primarily attributed to the absence of Revlimid sales and substantial R&D expenses. A one-time📎 pre-tax gain of ₹90 crores from a land sale contributed to the reported ₹76 crores in other income, mitigating the operational weakness.
Revlimid Outlook and Future Allocation
Management confirmed that there were no Revlimid sales in Q3 FY25 as the prior year's allocation was sold off by September end. However, the company is set to receive a one-third allocation of the total Revlimid market starting in Q4 FY25, with some portion expected to be sold in Q1. While specific quarterly sales figures were not provided, management expressed confidence in 'very well' performance in the coming quarters. The long-term outlook for Revlimid, however, includes a projected 'significant drop' of 50-60% in earnings post-March 2027 due to anticipated price erosion.
New Product Launches and Pipeline
Natco highlighted several key pipeline products. Semaglutide (injectable form) is a major focus for India, with an expected launch in March 2026, subject to regulatory approvals and resolution of other issues. The company aims to complete clinical trials by the end of the year and submit for permission. Risdiplam is another significant launch, with Natco being First-to-File and working with Sun Pharma, currently in early-stage litigation. Everolimus, with a total market size of approximately $120 million, has seen Natco secure a 50-50 share with its partners, with some portion expected to contribute to Q4 FY25 sales.
Financial Position and Capital Allocation
As of December 31, 2024, Natco Pharma maintains a robust financial position with ₹3,264 crores in cash and liquidity investments, and a net cash position of approximately ₹3,000 crores after accounting for ₹241 crores of debt. Despite the cash surplus, the company incurs finance costs due to short-term debt for foreign bill discounting and advance tax payments, borrowing at 6% while deposits yield 8%. Management reiterated its strategy to preserve cash for acquisitions, specifically targeting opportunities to strengthen its ROW business and US front-end portfolio in therapeutic prescription pharmaceuticals.
R&D Expenditure and Profitability Targets
R&D expenditure was noted as substantial in Q3 FY25, contributing to the quarter's weakness. Typically, R&D spending is maintained at 7-8% of net sales. For the full fiscal year, Natco expects to achieve a PAT of ₹1,800 to ₹2,000 crores in FY25, with similar expectations for FY26. Operating margins, excluding Revlimid, are estimated to be around 18-20%. The company acknowledges that its 'jackpot' driven business model inherently leads to earnings volatility, which investors must accept.
Crop Health Sciences Segment Performance
The Crop Health Sciences segment reported quarterly sales of approximately ₹15-16 crores and is currently operating at a loss. However, management has set a target for this segment to achieve breakeven by next year, with an ambitious revenue target of ₹120-150 crores for FY26. This growth is expected to contribute positively to the overall business, helping to offset some of the anticipated future earnings challenges.